A Sampling Of Citron's Most Influential Tweets

Citron Research activist short seller and newsletter author Andrew Left has earned a reputation for accusing companies of fraud and deception and profiting off of their downfall.

This week, Left turned his attention to 2016 market leader NVIDIA Corporation NVDA, tweeting that he believes the market “is disregarding headwinds” for the company and predicting shares would return to the $90 level in 2017. NVIDIA stock plunged 6.8 percent on the day of Citron’s tweet and were down 3 percent on the final trading session of the year.

Here’s a look at several other times Citron has moved the market with a tweet.

In December 2015, Citron tweeted that Express Scripts Holding Company ESRX was the “Philidor of the pharma industry.” The stock tanked 6.7 percent.

In November 2015, Citron tweeted that Mallinckrodt PLC MNK was a “far worse offender” of the drug reimbursement system than Valeant. Mallinckrodt stock plummeted 14 percent.

In March 2016, Citron targeted Tesla Motors Inc TSLA on Twitter, calling for the stock to dip “to $100 by year’s end.” The $100 prediction didn’t come true, but Tesla’s shares fell 3.1 percent following the tweet.

In June 2016, Left delivered a cryptic tweet about Facebook Inc FB, saying that he would not be commenting on Facebook and that the focus should “be on the Orlando tragedy and not mkt valuations.” Facebook shares dipped 2.2 percent.

In December 2015, Left tweeted that Mobileye NV MBLY was “short of the year” for 2016. Shares tanked nearly 7 percent.

In August 2016, Left tweeted that Japanese stock Cyberdyne was the “most ridiculous priced stock in the WORLD.” Shares plummeted 10 percent.

In September 2014, Left tweeted that Wall Street analyst were focused on “stock movement and not fundamentals” when it came to GoPro Inc GPRO. After Left disclosed Citron’s new short position, the stock fell 3.1 percent.

In June 2015, Left pointed out the “ridiculousness” of the fact that Ambarella Inc AMBA’s revenue was up 100 percent since its IPO, but the stock’s enterprise value had skyrocketed 6,000 percent. Shares nosedived 5.8 percent.

It wasn’t necessarily Left’s tweet in October 2015 that tanked Valeant Pharmaceuticals Intl Inc VRX’s stock nearly 40 percent, it was the famous damning Citron report the tweet referenced. Left made sure all of Citron’s Twitter followers knew they had found a “smoking gun” of deception in Valeant’s dealings with Philidor RX.

Posted In: Andrew LeftCitron ResearchLong IdeasShort SellersShort IdeasMediaTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.